查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1735639

全球原代细胞培养市场规模（依产品、应用、细胞类型、区域范围、预测）

Global Primary Cell Culture Market Size By Product (Primary Cell, Reagents And Supplements, Media), By Application (Vaccine Production, Stem Cell Therapy, Cancer Research), By Cell Type (Animal Cells, Human Cells), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

原代细胞培养市场规模及预测

2024 年原代细胞培养市场规模价值 45.3 亿美元，预计 2032 年将达到 107.1 亿美元，2026 年至 2032 年的复合年增长率为 11.37%。

  • 原代细胞培养是直接从组织分离细胞并在受控的实验室条件下培养细胞的过程。
  • 原代细胞培养在研究和开发中变得越来越重要，因为它们可以紧密模拟生物体细胞的生理行为，提供更准确的研究模型。
  • 在这种方法中，通常会从生物体中取出细胞并进行培养，而不会对其自然状态进行显着改变，从而确保保留重要的生物学特性。
  • 原代细胞培养在药物发现、毒理学、癌症研究和再生医学等领域的发展日益增多，它们被用于研究细胞行为、测试治疗剂和开发个人化治疗。
  • 对更准确、更可靠的体外模型的需求不断增长，进一步推动了原代细胞的使用，因为与连续细胞株相比，原代细胞更接近体内条件。
  • 培养中的原代细胞的生长需要特定的生长因子和营养物质的存在，这些生长因子和营养物质需要经过精心调节才能维持细胞活力和功能。
  • 生长因子，例如细胞激素和激素，对于促进这些培养物中的细胞增殖、分化和存活至关重要。

原代细胞培养的全球市场动态

影响全球原代细胞培养市场的关键市场动态是：

关键驱动因素

  • 个人化医疗需求不断增长：人们对个人化和精准医疗的兴趣日益增长，预计将推动原代细胞培养市场的发展，因为这些细胞对于开发针对特定患者的治疗方法至关重要。预计该市场将受益于对需要精确试管内模型的先进医疗疗法的投资不断增加。根据个人化医疗联盟的数据，预计在2017年至2022年期间，正在开发的个人化药物数量将增加34%，达到286治疗方法以上。
  • 专注于药物发现和开发：对药物发现的日益重视预计将加速原代细胞培养的应用，尤其是在疗效和毒性测试方面。这些细胞将透过提供更可靠的人体细胞模型，在减少对动物试验的依赖方面发挥关键作用。
  • 癌症研究投资：癌症研究投资庞大，培养细胞被广泛用于研究癌细胞的行为，预计将推动原代细胞培养市场的发展。全球癌症发生率的上升预计将刺激对先进细胞模型的需求，从而促进市场成长。
  • 3D细胞培养的应用不断扩大：3D细胞培养预计将提升原代细胞在研究中的相关性，因为它比传统的2D培养更能有效模拟体内环境。这一趋势可望扩大原代细胞培养在各研究领域的应用范围。根据VMR预测，2022年3D细胞培养市场规模将达到18.8亿美元，到2030年将达到43亿美元，2023年至2030年的复合年增长率为10.87%。

主要挑战

  • 原代细胞培养高成本：原代细胞培养过程的高成本，尤其是在研究资金有限的地区，预计将抑制市场成长。采购原代细胞和维持特定生长条件的费用预计将对市场扩张构成关键挑战。
  • 技术的复杂性和多变性：原代细胞培养的技术复杂性和固有的多变性可能会阻碍其广泛应用，并限制大规模研究和工业应用的可扩展性和可重复性。
  • 原代细胞供应有限：由于用于培养的人体和动物组织的采购仍然具有挑战性，高品质原代细胞供应有限预计将阻碍市场成长。围绕组织采购的伦理问题和监管限制预计将进一步限制供应链。
  • 污染风险和寿命短：与永生化细胞株相比，原代细胞的污染风险更高，寿命更短，这可能会限制市场发展。这些限制预计会增加实验室操作的挑战，并降低长期研究的效率。

主要趋势

  • 聚焦干细胞研究：再生医学对高品质原代细胞的需求正推动干细胞研究日益受到重视，预计这将对原代细胞培养市场产生重大影响。这一趋势可望推动生物技术和製药业的研发投资。
  • 产学合作：学术机构与生物製药公司之间日益增长的伙伴关係预计将推动原代细胞培养市场的发展。此类合作可望促进创新，并加速新型细胞治疗方法和研究工具的商业化。
  • 对先进组织工程的需求：对先进组织工程解决方案的旺盛需求预计将推动原代细胞培养在研究和临床应用中的应用。这一趋势将为类器官和生物工程组织的开发开闢新的途径，进一步扩大市场潜力。

目录

第一章 全球原代细胞培养市场简介

  • 市场介绍
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球原代细胞培养市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

第五章 全球原代细胞培养市场（依产品划分）

  • 概述
  • 原代细胞
  • 试剂和补充剂
  • 细胞培养基

第六章 全球原代细胞培养市场（依应用）

  • 概述
  • 疫苗生产
  • 干细胞治疗
  • 癌症研究
  • 其他的

7. 全球原代细胞培养市场（依细胞类型）

  • 概述
  • 动物细胞
  • 人类细胞

第八章全球原代细胞培养市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

第九章全球原代细胞培养市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第十章 公司简介

  • Thermo Fisher Scientific Inc.
  • Lonza
  • Merck KGaA
  • Axol Bioscience Ltd
  • GE Healthcare
  • STEMCELL Technologies Inc
  • Cell Biologics
  • ZenBio
  • ScienCell Research Laboratories
  • PPA Research Group

第十一章 重大进展

  • 产品发布/开发
  • 合併与收购
  • 业务扩展
  • 伙伴关係与合作

第十二章 附录

  • 相关调查
简介目录
Product Code: 35782

Primary Cell Culture Market Size And Forecast

Primary Cell Culture Market size was valued at USD 4.53 Billion in 2024 and is projected to reach USD 10.71 Billion by 2032, growing at a CAGR of 11.37% from 2026 to 2032.

  • Primary cell culture is the process by which cells are isolated directly from tissues and grown under controlled laboratory conditions.
  • The growing importance of primary cell culture in research and development is attributed to its ability to closely mimic the physiological behavior of cells within an organism, providing more accurate study models.
  • In this method, cells are typically harvested from a living organism and cultured without significant alterations to their natural state, ensuring the retention of critical biological characteristics.
  • Applications of primary cell cultures are rising in fields such as drug discovery, toxicology, cancer research, and regenerative medicine, where they are used to study cell behavior, test therapeutic agents, and develop personalized treatments.
  • The increasing demand for more precise and reliable in vitro models has further driven the use of primary cells, given their closer resemblance to in vivo conditions compared to continuous cell lines.
  • The growth of primary cells in culture requires the presence of specific growth factors and nutrients, which are carefully regulated to maintain cellular viability and function.
  • Growth factors, such as cytokines and hormones, are essential for promoting cell proliferation, differentiation, and survival in these cultures.

Global Primary Cell Culture Market Dynamics

The key market dynamics that are shaping the global primary cell culture market include:

Key Drivers:

  • Growing Demand for Personalized Medicine: The rising interest in personalized and precision medicine is anticipated to drive the primary cell culture market, as these cells are integral to developing patient-specific therapies. The market is expected to benefit from increasing investments in advanced medical treatments that require accurate in vitro models. According to the Personalized Medicine Coalition, the number of personalized medicines in development increased by 34% between 2017 and 2022, reaching over 286 therapies.
  • Focus on Drug Discovery and Development: The increasing focus on drug discovery is projected to accelerate the adoption of primary cell cultures, especially for testing efficacy and toxicity. These cells are likely to play a critical role in reducing reliance on animal testing by offering more reliable human-based cell models.
  • Investments in Cancer Research: High investments in oncology research are expected to fuel the primary cell culture market, with these cultures being widely used in studying cancer cell behavior. Rising cancer incidence globally is anticipated to boost demand for advanced cellular models, increasing market growth.
  • Growing Use of 3D Cell Cultures: The adoption of 3D cell cultures in research is estimated to enhance the relevance of primary cells, given their ability to replicate in vivo environments more effectively than traditional 2D cultures. This trend is expected to expand the application range of primary cell cultures in various research domains. According to VMR, 3D Cell Culture Market size was valued at USD 1.88 Billion in 2022 and is projected to reach USD 4.30 Billion in 2030, at a CAGR of 10.87% from 2023 to 2030.

Key Challenges:

  • High Costs of Primary Cell Cultures: The high costs associated with primary cell culture processes are anticipated to restrain market growth, particularly in regions with limited research funding. The expense of procuring primary cells and maintaining specific growth conditions is expected to be a key challenge for market expansion.
  • Technical Complexity and Variability: The technical complexity and inherent variability of primary cell cultures are likely to impede widespread adoption. This challenge is projected to limit scalability and reproducibility in large-scale research and industrial applications.
  • Limited Availability of Primary Cells: The limited availability of high-quality primary cells is expected to hamper market growth, as sourcing human or animal tissues for these cultures remains difficult. Ethical concerns and regulatory restrictions around tissue procurement are anticipated to further restrain supply chains.
  • Contamination Risks and Shorter lifespan: The higher risk of contamination and the shorter lifespan of primary cells compared to immortalized cell lines are likely to restrain the market. These limitations are expected to increase operational challenges for laboratories, reducing the efficiency of long-term studies.

Key Trends:

  • Focus on Stem Cell Research: The rising emphasis on stem cell research is expected to significantly influence the primary cell culture market, given the need for high-quality primary cells in regenerative medicine. This trend is likely to enhance investment in research and development across the biotechnology and pharmaceutical sectors.
  • Collaboration between Academia and Industry: Growing partnerships between academic institutions and biopharmaceutical companies are projected to boost the primary cell culture market. These collaborations are anticipated to drive innovation and expedite the commercialization of new cell-based therapies and research tools.
  • Demand for Advanced Tissue Engineering: The high demand for advanced tissue engineering solutions is expected to drive the adoption of primary cell cultures in research and clinical applications. This trend is likely to open new avenues for developing organoids and bioengineered tissues, further expanding market potential.

Global Primary Cell Culture Market Regional Analysis

Here is a more detailed regional analysis of the global primary cell culture market:

North America:

  • According to Verified Research Market Analyst, North America is anticipated to dominate the primary cell culture market due to the presence of advanced biotechnology and pharmaceutical industries.
  • The United States is projected to lead the regional market, driven by increasing investments in research and development, as well as the growing focus on personalized medicine and drug discovery.
  • A well-established healthcare infrastructure and strong academic-industry collaborations are expected to further support market growth in this region.
  • The rising prevalence of chronic diseases such as cancer is also likely to drive demand for primary cell cultures in North American research institutions. The American Cancer Society estimates that there will be 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States in 2024.

Asia Pacific:

  • The Asia Pacific region is estimated to experience the fastest growth in the primary cell culture market, driven by the rising investment in biotechnology and pharmaceutical sectors in countries such as China, Japan, and India.
  • According to VMR, Biotechnology Market size was valued at USD 1023.92 Billion in 2023 and is projected to reach USD 2590.03 Billion by 2032, growing at a CAGR of 12.3% from 2026 to 2032.
  • The increasing government initiatives to promote life sciences research, along with the expanding clinical research activities, are projected to propel market growth in the region.
  • China's growing biotechnology industry, combined with its focus on innovation and healthcare, is anticipated to significantly boost the market for primary cell cultures.
  • India is also likely to witness rapid growth, driven by a rising number of pharmaceutical companies and a growing focus on drug development and testing.

Global Primary Cell Culture Market: Segmentation Analysis

The Global Primary Cell Culture Market is Segmented on the basis of Product, Application, Cell Type, And Geography.

Primary Cell Culture Market, By Product

  • Primary Cell
  • Reagents And Supplements
  • Media

Based on Product, the market is bifurcated into Primary Cell, Reagents And Supplements, and Media. The media segment is anticipated to hold the largest share of the primary cell culture market due to its critical role in supporting cell growth, proliferation, and differentiation. Media is projected to experience sustained demand as it is essential for maintaining the viability and functionality of primary cells throughout research and production processes.

Primary Cell Culture Market, By Application

  • Vaccine Production
  • Stem Cell Therapy
  • Cancer Research

Based on Application, the Global Primary Cell Culture Market is divided into Vaccine Production, Stem Cell Therapy, and Cancer Research. The vaccine production segment is projected to hold the largest share of the primary cell culture market. The increasing use of primary cells in the development and production of vaccines is anticipated to drive this growth. Primary cells are widely used due to their ability to mimic natural human cell environments, which is crucial for creating vaccines that are safe and effective.

Primary Cell Culture Market, By Cell Type

  • Animal Cells
  • Human Cells

Based on Cell Type, the market is segmented into Animal Cells and Human Cells. Human cells are anticipated to hold the largest share of the primary cell culture market, driven by their increasing application in drug discovery, personalized medicine, and cancer research. The demand for human primary cells is projected to rise due to their ability to provide more accurate and clinically relevant models for studying human physiology and disease.

Primary Cell Culture Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
  • On the basis of Geography, the global primary cell culture market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America held the largest share of the primary cell culture market, driven by its advanced biotechnology and pharmaceutical industries. The region is projected to maintain its dominance due to the increasing focus on personalized medicine and rising investments in drug discovery and development.

Key Players

The "Global Primary Cell Culture Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Thermo Fisher Scientific, Merck KGaA, Lonza, Corning Incorporated, Danaher Corporation, GE Healthcare, PromoCell GmbH, American Type Culture Collection, FUJIFILM Irvine Scientific, MatTek Ltd, Axol Bioscience Ltd, STEMCELL Technologies Inc, Cell Biologics, ZenBio, ScienCell Research Laboratories, and PPA Research Group. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Latest Developments

  • In March 2024, Lonza announced a collaboration with a renowned biopharmaceutical company to develop a new cell culture medium tailored exclusively for breakthrough cell therapy.
  • In February 2024, Thermo Fisher Scientific introduced a new line of cryopreserved primary human hepatocytes, seeking to give researchers with a more consistent and trustworthy source of these cells for drug discovery applications.
  • In February 2024, Corning Incorporated expanded its portfolio of Transwell(R) co-culture devices, which are intended to increase the efficiency and accuracy of cell-based assays used in drug development.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PRIMARY CELL CULTURE MARKET

  • 1.1 Introduction of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL PRIMARY CELL CULTURE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL PRIMARY CELL CULTURE MARKET, BY PRODUCT

  • 5.1 Overview
  • 5.2 Primary Cell
  • 5.3 Reagents And Supplements
  • 5.4 Media

6 GLOBAL PRIMARY CELL CULTURE MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Vaccine Production
  • 6.3 Stem Cell Therapy
  • 6.4 Cancer Research
  • 6.5 Others

7 GLOBAL PRIMARY CELL CULTURE MARKET, BY CELL TYPE

  • 7.1 Overview
  • 7.2 Animal Cells
  • 7.3 Human Cells

8 GLOBAL PRIMARY CELL CULTURE MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL PRIMARY CELL CULTURE MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Thermo Fisher Scientific Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Lonza
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Merck KGaA
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Axol Bioscience Ltd
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 GE Healthcare
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 STEMCELL Technologies Inc
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Cell Biologics
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 ZenBio
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 ScienCell Research Laboratories
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 PPA Research Group
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research